These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1845044)
41. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
42. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. Montefiori DC; Evans TG AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464 [No Abstract] [Full Text] [Related]
43. Antibody response to the negative regulatory factor (nef) in experimentally infected macaques: correlation with viremia, disease progression, and seroconversion to structural viral proteins. Kirchhoff F; Voss G; Nick S; Stahl-Hennig C; Coulibaly C; Frank R; Jentsch KD; Hunsmann G Virology; 1991 Jul; 183(1):267-72. PubMed ID: 1675823 [TBL] [Abstract][Full Text] [Related]
44. Cross reaction. Could AIDS really be an autoimmune disease? Beardsley T Sci Am; 1991 Dec; 265(6):56-7. PubMed ID: 1754873 [No Abstract] [Full Text] [Related]
45. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113 [TBL] [Abstract][Full Text] [Related]
46. [Development of HIV vaccines]. Shibata R Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790 [TBL] [Abstract][Full Text] [Related]
47. Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. O'Hagan DT; Rafferty D; McKeating JA; Illum L J Gen Virol; 1992 Aug; 73 ( Pt 8)():2141-5. PubMed ID: 1645152 [TBL] [Abstract][Full Text] [Related]
48. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112 [TBL] [Abstract][Full Text] [Related]
49. Antigenicity of the HIV-2 V3 loop. Jones IM; Morikawa Y; Fenouillet E; Moore JP AIDS; 1992 Aug; 6(8):888-9. PubMed ID: 1418793 [No Abstract] [Full Text] [Related]
50. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
51. Development of an AIDS vaccine: a daunting epidemiological challenge. Nathanson N; Mathieson BJ Eur J Epidemiol; 2005; 20(2):123-6. PubMed ID: 15792276 [No Abstract] [Full Text] [Related]
52. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail. Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291 [No Abstract] [Full Text] [Related]
53. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses. Hewer R; Meyer D Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588 [TBL] [Abstract][Full Text] [Related]
55. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF; Green TD; Ross TM Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849 [TBL] [Abstract][Full Text] [Related]
56. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions. Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113 [TBL] [Abstract][Full Text] [Related]